Li Xiaowei, Fu Zhigang, Zhong Jiaming, Cao Kunkun, Chen Xiaoxia, Ding Ning, Liu Li, Zhai Jian, Qu Zengqiang
Department II of Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
J Interv Med. 2022 Feb 26;5(1):46-49. doi: 10.1016/j.jimed.2021.12.007. eCollection 2022 Feb.
Hepatocellular carcinoma (HCC) is the most commonly diagnosed carcinoma and one of the leading causes of cancer-related deaths worldwide. Situs inversus totalis (SIT) is a congenital condition where in the internal organs of the abdomen and thorax lie in mirror images of their normal position. Thus far, there are very few reports on cases of SIT coexisting with HCC. Our case series is probably the largest series in world literature. The cohort of this retrospective study included a total of nine patients diagnosed with SIT-HCC and treated in our hospital between January 2013 and May 2018. Clinical characteristics, prognostic factors, and outcomes were summarized. Treatment strategies included surgery, transarterial chemoembolization, and microwave ablation. The diagnosis and treatment of patients with SIT are challenging because of organ reversion. The current treatment strategies for different stages of liver cancer are safe and feasible for patients with SIT-HCC.
肝细胞癌(HCC)是最常被诊断出的癌症,也是全球癌症相关死亡的主要原因之一。全内脏反位(SIT)是一种先天性疾病,其腹部和胸部的内部器官处于正常位置的镜像状态。迄今为止,关于SIT与HCC共存病例的报道非常少。我们的病例系列可能是世界文献中最大的系列。这项回顾性研究的队列包括2013年1月至2018年5月期间在我院诊断为SIT-HCC并接受治疗的9名患者。总结了临床特征、预后因素和结果。治疗策略包括手术、经动脉化疗栓塞和微波消融。由于器官反转,SIT患者的诊断和治疗具有挑战性。目前针对不同阶段肝癌的治疗策略对SIT-HCC患者是安全可行的。